CASE REPORT

Case Report: A case report of acromegaly associated with primary aldosteronism [version 2; referees: 2 approved]

Joanna Matrozova, Silvia Vandeva, Sabina Zacharieva
Clinical Center of Endocrinology and Gerontology, Medical University – Sofia, 1431, Sofia, Bulgaria

Abstract
We describe a patient with a rare combination of acromegaly and primary aldosteronism. A 37 year-old female patient was diagnosed with acromegaly on the basis of typical clinical, hormonal and image characteristics. She presented also with one of the most common co-morbidities – arterial hypertension. The patient has been regularly followed-up and after three surgical interventions, irradiation and adjuvant treatment with a dopamine agonist, acromegaly was finally controlled in 2008 (20 years after diagnosis). Arterial hypertension however, remained a therapeutic problem even after prescription of four antihypertensive drugs. She had normal biochemical parameters, except for low potassium levels 3.2 (3.5-5.6) mmol/l. This raised the suspicion of primary hyperaldosteronism, confirmed by a high aldosterone to plasma rennin activity ratio, high aldosterone level after a Captopril challenge test and visualization of a 35 mm left adrenal nodule on a CT scan. After an operation, the patient recovered from hypokalemia and antihypertensive therapy was reduced to a small dose of a Ca blocker.

Co-morbid arterial hypertension is common in acromegaly, though it is rare for this to be caused by Conn’s adenoma. The association of Conn’s adenoma with acromegaly has been interpreted in two lines: as a component of multiple endocrine neoplasia type (MEN1) syndrome or as a direct mitogenic effect of hyperactivated GH-IGF1 axis.

Corresponding author: Joanna Matrozova (jmatrozova@yahoo.com)


Grants: This work was supported by grants from the Medical University of Sofia (Grant No. 385/2013) and the Sofia City Council (Grant No. 1007/2013).

Copyright: © 2014 Matrozova J et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Grant information: The author(s) declared that no grants were involved in supporting this work.

Competing interests: No competing interests were disclosed.

**Amendments from Version 1**

The new version of the article has one additional sentence admitting the possibility of a mere coincidence in the co-existence of acromegaly and Conn’s adenoma.

**See referee reports**

**Introduction**

In the literature several patients with primary aldosteronism (PA) associated with endocrine and non-endocrine tumors have been reported1-3. These cases were attributed mainly to multiple endocrine neoplasia type 1 (MEN1), which is an autosomal dominantly inherited condition, characterized by the association of tumors of the pituitary and the parathyroid glands, the endocrine pancreas, the adrenal glands and neuroendocrine tumors. Aldosterone-producing adenomas have been described in various combinations, mainly with hyperparathyroidism, prolactinomas and pancreatic endocrine tumors, but none of these have been associated with acromegaly2,3,4.

On the other hand, the prevalence of adrenal lesions in sporadic cases of acromegaly is higher than in the general population, possibly due to the permissive role of growth hormone (GH) and insulin-like growth factor 1 (IGF1) on tumorigenesis5-8. Previously benign, non-secreting adrenal tumors have been described in patients with acromegaly6-8. However, to our knowledge the association between acromegaly and Conn’s adenoma in sporadic acromegaly has been reported only in isolated cases9,10.

We describe herein a case of acromegaly, associated with PA due to an aldosterone-producing adenoma of the adrenal gland.

**Case report**

In May 2008, a 57 year-old, Caucasian woman with a 20 year history of acromegaly was hospitalized in our clinic for a regular follow-up. Acromegaly was diagnosed in 1988 on the basis of a GH of 9.3 mIU/L, which was not suppressed during a glucose tolerance test (OGTT; GH 13.6 mIU/L) and a macroadenoma of the pituitary gland visualized on CT. Prolactin levels were also high: 3300 mIU/l test (OGTT; GH 13.6 mIU/L) and a macroadenoma of the pituitary was visualized on CT. Prolactin levels were also high: 3300 mIU/l test (OGTT; GH 13.6 mIU/L). Acromegaly was diagnosed in 1988 on the basis of a GH of 9.3 mIU/L.

In 1994, she was treated with radiotherapy and in the period between 1994 and 2001 she received dopamine agonists (15 mg daily of bromocriptine for six years and 2×0.5 mg weekly cabergoline for the last four months of the period). Acromegaly was still not controlled and a treatment with a somatostatin analogue (vapreotide s.c. implant, 396 mg every 12 weeks) was started in 2001. The patient was estimated to be a partial responder with no significant improvement in hormonal parameters, so she was switched back to 2×0.5 mg weekly dose of cabergoline. The MRI from 2008 showed a tumor remnant of 18 mm, spreading towards the right part of the sphenoidal sinus.

The patient had a past medical history of multinodular goiter, operated on in 2001 and recurrent in 2008. She has been hypertensive since she was 37 years old. Her hypertension has never been well controlled on a triple therapy, including a diuretic (enalapril maleate 2×20 mg, nifedipine 4×10 mg and chlortalidone 100 mg daily). She was operated on for a colon polyp in 1994 and was followed-up for myoma of the uterus. Family history of hypertension was recorded with both parents being hypertensive.

On admission in 2008 she was 1.70 m tall, weighed 83 kg with a waist circumference of 89 cm and had a BMI of 29. Her blood pressure was 150/90 mmHg. Arterial blood pressure monitoring (ABPM) showed a mean daily systolic blood pressure (SBP) of 150 mmHg and diastolic blood pressure (DBP) of 93 mmHg. At that time she showed a mean daily systolic blood pressure (SBP) of 150 mmHg twice a day, enalapril 20 mg twice a day, indapamide 2.5 mg per day, prazosin 0.5 mg per day, and cabergoline 2×0.5 mg weekly. Physical examination showed typical acromegalic features such as enlargement of the hands and feet, deep nasolabial folds and macroglossia.

The association of resistant hypertension and hypokalemia raised the suspicion of PA. Baseline laboratory data are shown in Table 1. Treatment with ACE-inhibitors and diuretics was stopped for 20 days to was performed in the same year and another one in 1991 after growth of the remnant tumor mass. Histology conducted in 1988 showed somatoprolactinoma. In 1993, she had a transcranial adenomectomy due to remnant macroadenoma. As the disease activity (i.e. GH hypersecretion and presence of tumor mass) still persisted, in 1994 she was treated with radiotherapy and in the period between 1994 and 2001 she received dopamine agonists (15 mg daily of bromocriptine for six years and 2×0.5 mg weekly cabergoline for the last four months of the period). Acromegaly was still not controlled and a treatment with a somatostatin analogue (vapreotide s.c. implant, 396 mg every 12 weeks) was started in 2001. The patient was estimated to be a partial responder with no significant improvement in hormonal parameters, so she was switched back to 2×0.5 mg weekly dose of cabergoline. The MRI from 2008 showed a tumor remnant of 18 mm, spreading towards the right part of the sphenoidal sinus.

On admission in 2008 she was 1.70 m tall, weighed 83 kg with a waist circumference of 89 cm and had a BMI of 29. Her blood pressure was 150/90 mmHg. Arterial blood pressure monitoring (ABPM) showed a mean daily systolic blood pressure (SBP) of 150 mmHg and diastolic blood pressure (DBP) of 93 mmHg. At that time she was treated with nitrendipine 20 mg twice a day, enalapril 20 mg twice a day, indapamide 2.5 mg per day, prazosin 0.5 mg per day, and cabergoline 2×0.5 mg weekly. Physical examination showed typical acromegalic features such as enlargement of the hands and feet, deep nasolabial folds and macroglossia.

The association of resistant hypertension and hypokalemia raised the suspicion of PA. Baseline laboratory data are shown in Table 1. Treatment with ACE-inhibitors and diuretics was stopped for 20 days to

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Result</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting blood glucose, mmol/l</td>
<td>4.62</td>
<td>3.89–6.1</td>
</tr>
<tr>
<td>Total cholesterol, mmol/l</td>
<td>5.35</td>
<td>&lt;5.2</td>
</tr>
<tr>
<td>Triglycerides, mmol/l</td>
<td>0.78</td>
<td>&lt;1.72</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/l</td>
<td>1.68</td>
<td>&gt;1.3</td>
</tr>
<tr>
<td>Creatinine, µmol/l</td>
<td>53</td>
<td>&lt;106</td>
</tr>
<tr>
<td>Potassium, mmol/l</td>
<td>3.2–3.6</td>
<td>3.5–5.6</td>
</tr>
<tr>
<td>IGF1, nmol/l</td>
<td>26.8</td>
<td>14–40.5</td>
</tr>
<tr>
<td>GH in the course of glucose</td>
<td>0 min 3.7</td>
<td>GH&lt;5 mIU/l (2 ng/ml) during OGTT</td>
</tr>
<tr>
<td>tolerance test, mIU/l</td>
<td>60 min 2.9</td>
<td>at baseline and</td>
</tr>
<tr>
<td></td>
<td>120 min 2.1</td>
<td>GH&lt;2.5 mIU/l (1 ng/ml)</td>
</tr>
<tr>
<td>FT4, pmol/l</td>
<td>12.5</td>
<td>9–23</td>
</tr>
</tbody>
</table>

IGF1- insulin-like growth factor-1, GH- growth hormone, FT4- free thyroxine
investigate her Renin-Angiotensin-Aldosterone-System (RAAS) before the next presentation to our clinic. In our unit the aldosterone to renin ratio (ARR) is used as a screening test for PA. In patients with elevated basal ARR (>750 pmol/l per ng/ml/h) a confirmatory test (Captopril challenge test) was performed. The diagnosis of PA is confirmed if the aldosterone is >330 pmol/l at the 90th minute after the oral administration of mg of Captopril, with the patient asked to remain in a sitting position throughout the test. In our patient the basal and post-captopril aldosterone to renin ratio was 1260 and 3545, respectively. Suppressed plasma rennin activity (PRA) was measured at the beginning and the end of the test (<0.2 ng/ml, normal range 0.3–3). Basal aldosterone was 252 pmol/l and 709 pmol/l at the end of the test. The adrenal CT scan showed a 35 mm nodule in the left adrenal gland (Figure 1) and aldosterone-producing adenoma (Conn’s adenoma) was diagnosed. The patient was operated on in August 2008. A tumor of 35 mm was found and histology (hematoxylin and eosin) data showed a tumor of adrenal cortex origin, consisting of light cells.

The patient had a follow-up visit three months after the operation. Recovery from hypokalemia was recorded (potassium: 4.95 mmol/l). Over this period the antihypertensive therapy was reduced and she was receiving only a small dose of a Ca blocker (nitrendipine 40 mg daily). Her blood pressure was 130/80 mmHg. ABPM showed a mean daily SBP of 138 mmHg and a DBP of 83 mmHg, and a mean heart rate of 53 bpm. A Captopril test was performed which revealed normal aldosterone levels with a tendency to low renin values: 0 min PRA 0.3 ng/ml/h, aldosterone 82 pmol/l, ARR 273; 90 min PRA 0.3 ng/ml/h, aldosterone 98.9 pmol/l, ARR 329.

In the last three years of her regular follow-up visits the patient was found to be normokalemic and normotensive on a double antihypertensive therapy (ACE-inhibitor and Ca blocker). Her most recent visit to our unit was in June 2013. Acromegaly was well controlled with slightly elevated blood pressure, well controlled using small doses of an ACE-inhibitor (10 mg daily lisinopril) and a Ca-blocker (20 mg daily nifedipine). Laboratory data showed normal potassium of 5.1 mmol/l. The association of acromegaly and Conn’s adenoma raised the hypothesis for MEN1 in our patient, therefore the parathyroid glands were investigated using ultrasound. There were no clinical, laboratory or ultrasound data for primary hyperparathyroidism. Biochemical parameters were normal: serum calcium levels were 2.42 mmol/l (normal range: 2.12–2.62) and phosphorus was 1.35 (normal range: 0.87–1.45). The ultrasound image was not suspicious for parathyroid adenoma. The patient had no relatives with endocrine tumors.

Discussion

We describe a rare combination of acromegaly and PA due to an aldosterone-producing adenoma. There are several recent reports which describe the association of PA and different types of tumors. These cases are related mainly to MEN1. MEN1 is caused by germline mutations of the menin gene, which most frequently leads to the development of primary hyperparathyroidism, pituitary adenomas and pancreatic tumors. The prevalence of pituitary tumors in MEN1 varies according to different studies, from 10 to 76%.

Somatotropinomas causing acromegaly occur in 3–6% of MEN1 patients. As for adrenal involvement in patients with MEN1, the data are contradictory with a prevalence ranging from 9 to 73% depending on the investigated series. A recent large study in 715 MEN1 patients showed adrenal lesions in 146 cases, and among them 72 had adrenal adenomas, comprising 10% of the whole cohort. Four cases of PA were found in the whole group. None of them was associated with acromegaly, but rather with primary hyperparathyroidism, prolactinoma, or pancreatic endocrine tumors.

In the literature only single cases of PA have been described in MEN1. Beckers et al. reported a case of PA as a part of MEN1, associated with parathyroid adenoma, prolactinoma and toxic multinodular goiter. Kim et al. described a case of PA, associated with primary hyperparathyroidism, Hurthle cell thyroid cancer and meningioma with a loss of heterozygosity (LOH) of the MEN1 locus in parathyroid glands, but no germline mutation. Honda et al. reported PA associated with primary hyperparathyroidism and breast cancer and a LOH of the MEN1 locus in the parathyroid adenoma and in the breast cancer tissue. None of the reported cases was associated with acromegaly, in contrast to our patient. Although investigations for primary hyperparathyroidism were negative in our case, the patient showed two endocrine tumors over several years, which could be related to the presence of MEN1. This could not be confirmed as genetic analysis was not performed due to funding restrictions, which is a serious weak point of the case presentation. However, in different series in up to 60% of patients with a sporadic MEN1 phenotype, no mutation of the corresponding menin gene has been found.

On the other hand we could speculate that the activated GH-IGF1 axis may have a role in the morphological and functional adrenal changes in aldosterone-producing adenomas in acromegaly. Although the incidence of neoplasms in acromegaly is a matter of debate, numerous
reports have suggested that patients are at increased risk of developing thyroid nodules and colon polyps\(^8\), as well as thyroid cancer\(^1\), breast cancer\(^2\), and colorectal cancer\(^3\). There are limited data in the literature concerning the adrenal involvement in acromegalic patients. In a study by Scaroni et al. adrenal morphological abnormalities were found in 28.7% of acromegalic patients (n=94), among them nine cases with unilateral adenoma and the rest with uni- or bilateral hyperplasia. All tumors were hormonally inactive and no cases of PA were found.

Another recent study found an even higher prevalence of adrenal abnormalities in patients with acromegaly, describing abnormal adrenal morphology in 48% of patients in a group with 670 acromegals. Among them 19 patients had an adrenal adenoma, 10 subjects had adrenal hyperplasia and 7% had hyperaldosteronism\(^4\). The increased prevalence of adrenal incidentaloma in acromegaly suggests that GH and IGF1 may have an effect on adrenal morphological changes, although in both studies cited above, no significant correlation with GH-IGF1 were found. On the other hand, it has been shown that IGF1 factors are potent mitogens and a strong IGFI expression has been demonstrated in adrenocortical tumors\(^5\). Also, a recent study demonstrated that the GH receptor is expressed in both normal rat and normal and diseased human adrenals, which suggests direct action of GH in adrenal tissue\(^6\).

From a functional point of view several studies have explored the interactions between the GH-IGF1 axis and RAAS. A stimulatory effect of the GH/IGF1 on RAAS has been demonstrated in some reports\(^7,8\). A recent study by Bielohuby et al.\(^9\) showed increased levels of aldosterone in acromegalic patients which normalized after surgery. Aldosterone levels were elevated in a transgenic mouse model over-expressing GH compared to non-transgenic mice and changes in aldosterone were independent of IGF1, renin and the expression of aldosterone synthase\(^1\). These studies suggest a direct effect of GH on adrenal glands, which could lead to abnormalities of function or morphology and eventually to the formation of an aldosterone-producing adenoma as may have occurred in our patient. Finally, we could not exclude the possibility of a mere coincidence in the co-existence of both pathologies.

**Conclusion**

We have described an uncommon case of two endocrine tumors – somatoprolactinoma and Conn’s adenoma diagnosed years after initial presentation of acromegaly. This combination could be part of the MEN1 syndrome, despite the absence of hyperparathyroidism. On the other hand, our patient already had several co-morbidities due to the mitogenic effect of the GH-IGF1 hyperactivation (multinodular goiter, myoma and colon polyp), which is another plausible hypothesis for the functional and structural changes in the adrenal gland.

**Consent**

Written informed consent for publication of clinical details and clinical images was obtained from the patient.

**Author contributions**

Joanna Matrozoia and Silvia Vandevo wrote the manuscript, Sabina Zacharieva revised the manuscript. All the authors approved the final manuscript for publication.

**Competing interests**

No competing interests were disclosed.

**Grant information**

The author(s) declared that no grants were involved in supporting this work.

**References**


Open Peer Review

Current Referee Status: ✔ ✔

Version 2

Referee Report 26 June 2014
doi:10.5256/f1000research.4622.r5242

Niki Karavitaki
Department of Endocrinology, Oxford Centre for Diabetes, The Churchill Hospital, University of Oxford, Oxford, UK

The presented case is interesting.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Version 1

Referee Report 25 June 2014
doi:10.5256/f1000research.4622.r5243

Shlomo Melmed
Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Shlomo Melmed
Pituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

This is a well described case of interest to readers. It is clearly written and contains important information.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Competing Interests:** No competing interests were disclosed.

---

Referee Report 10 March 2014
doi:10.5256/f1000research.3454.r3909

**Niki Karavitaki**
Department of Endocrinology, Oxford Centre for Diabetes, The Churchill Hospital, University of Oxford, Oxford, UK

This is an interesting case of a patient with co-existing acromegaly and primary aldosteronism attributed to a Conn's adenoma.

Although the biochemical confirmation of primary aldosteronism relied only on a Captopril test and no adrenal vein sampling took place, the improvement of the blood pressure control and the resolution of hypokalaemia following the removal of the adrenal mass support the diagnosis of Conn's adenoma.

The authors attempt to provide a pathophysiological link between the two conditions. Their thoughts are very interesting but the option of a mere coincidence also needs to be mentioned.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

**Competing Interests:** No competing interests were disclosed.

---

Author Response (Member of the F1000 Faculty) 22 May 2014

**Silvia Vandeva,** Clinical Center of Endocrinology and Gerontology 'Akad Iv Pentchev', Sofia Medical University, Bulgaria

Dear prof. Melmed,

The authors thank you for your comments.

**Competing Interests:** No competing interests were disclosed.

---

Author Response (Member of the F1000 Faculty) 22 May 2014

**Silvia Vandeva,** Clinical Center of Endocrinology and Gerontology 'Akad Iv Pentchev', Sofia Medical University, Bulgaria

Dear Dr Karavitaki,

The authors thank you for your comments. We have conformed to your recommendations.

**Competing Interests:** No competing interests were disclosed.